Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 7 | -$1.78 | -$0.64 | -$1.10 |
| Q2 2026 | 4 | -$1.92 | -$0.76 | -$1.09 |
| Q3 2026 | 3 | -$2.09 | -$0.83 | -$1.19 |
| Q4 2026 | 2 | -$2.16 | -$0.85 | -$1.23 |
| Q1 2027 | 2 | -$0.66 | -$0.26 | -$0.37 |
| Q2 2027 | 2 | -$0.70 | -$0.28 | -$0.40 |
| Q3 2027 | 2 | -$0.75 | -$0.30 | -$0.43 |
| Q4 2027 | 2 | -$0.81 | -$0.32 | -$0.46 |
AnaptysBio, Inc. last posted its earnings results on Tuesday, November 4th, 2025. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $-1.06 by $1.58. The company had revenue of 76.32 M for the quarter and had revenue of 91.28 M for the year. AnaptysBio, Inc. has generated $-5 earnings per share over the last year ($-5.12 diluted earnings per share) and currently has a price-to-earnings ratio of -16.46. AnaptysBio, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 9th, 2026 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/04/2025 | Q3 2025 | -$1.06 | $0.54 | 1.6 | $21.92 M | $76.32 M |
| 08/06/2025 | Q2 2025 | -$1.50 | -$1.34 | 0.16 | $11.68 M | $22.26 M |
| 05/05/2025 | Q1 2025 | -$1.30 | -$1.28 | 0.02 | N/A | $27.77 M |
| 02/27/2025 | Q4 2024 | -$1.61 | -$0.77 | 0.84 | N/A | $43.11 M |
| 11/05/2024 | Q3 2024 | -$1.72 | -$1.14 | 0.58 | $8.21 M | $30.02 M |
| 08/05/2024 | Q2 2024 | -$1.20 | -$1.71 | -0.51 | $22.76 M | $10.97 M |
| 05/09/2024 | Q1 2024 | -$1.54 | -$1.64 | -0.1 | N/A | $7.18 M |
| 03/11/2024 | Q4 2023 | -$1.74 | -$1.57 | 0.17 | N/A | $9.01 M |
| 11/02/2023 | Q3 2023 | -$1.72 | -$1.41 | 0.31 | N/A | $3.32 M |
| 08/07/2023 | Q2 2023 | -$1.65 | -$1.50 | 0.15 | N/A | $3.46 M |
| 05/11/2023 | Q1 2023 | -$1.04 | -$1.73 | -0.69 | N/A | $1.37 M |
| 03/01/2023 | Q4 2022 | -$0.92 | -$0.93 | -0.01 | N/A | $6.81 M |
| 11/08/2022 | Q3 2022 | -$0.47 | -$1.32 | -0.85 | N/A | $1.29 M |
| 08/08/2022 | Q2 2022 | -$0.95 | -$1.32 | -0.37 | N/A | $1.22 M |
| 05/04/2022 | Q1 2022 | -$0.87 | -$1.47 | -0.6 | N/A | $970.00 K |
| 03/07/2022 | Q4 2021 | $2.28 | -$1.18 | -3.46 | N/A | $1.01 M |
| 11/04/2021 | Q3 2021 | -$0.74 | -$0.24 | 0.5 | N/A | $20.89 M |
| 08/09/2021 | Q2 2021 | -$0.15 | -$0.02 | 0.13 | N/A | $30.03 M |
| 05/04/2021 | Q1 2021 | -$0.71 | -$0.66 | 0.05 | N/A | $11.25 M |
| 02/25/2021 | Q4 2020 | $1.39 | $1.23 | -0.16 | N/A | $60.00 M |
AnaptysBio, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 9th, 2026 based offlast year's report dates.
In the previous quarter, AnaptysBio, Inc. (:ANAB) reported $0.52 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.06 by $1.58.
The conference call for AnaptysBio, Inc.'s latest earnings report can be listened to online.
The conference call transcript for AnaptysBio, Inc.'s latest earnings report can be read online.
AnaptysBio, Inc. (:ANAB) has a recorded annual revenue of $91.28 M.
AnaptysBio, Inc. (:ANAB) has a recorded net income of $-145,231,000.AnaptysBio, Inc. has generated $-5.12 earnings per share over the last four quarters.
AnaptysBio, Inc. (:ANAB) has a price-to-earnings ratio of -16.46 and price/earnings-to-growth ratio is -0.44.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED